This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Estimates Rising for BellRing Brands (BRBR): Will It Gain?
by Zacks Equity Research
BellRing Brands (BRBR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx
by Zacks Equity Research
Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.
QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat
by Zacks Equity Research
QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.
Should Value Investors Buy BellRing Brands (BRBR) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump
by Zacks Equity Research
The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
by Zacks Equity Research
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty
by Zacks Equity Research
Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.
Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant
by Zacks Equity Research
Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Here's Why You Should Retain Haemonetics (HAE) Stock for Now
by Zacks Equity Research
Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.
Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch
by Zacks Equity Research
Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.
Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact
by Zacks Equity Research
Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.
Cardiovascular Systems (CSII) Introduces Diamondback in Canada
by Zacks Equity Research
The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
Hill-Rom (HRC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on impressive third-quarter fiscal 2021 performance and raised 2021 guidance.
Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario
by Zacks Equity Research
LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Medtronic's (MDT) Micra TPS CED Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.
Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges
by Zacks Equity Research
According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.
Walgreens (WBA) Provides Flu Shots Nationwide for Ages 3 & More
by Zacks Equity Research
Walgreens (WBA) is ready to co-administer COVID-19 vaccines and flu shots anticipating COVID-19 boosters in September.
Omnicell (OMCL) Enhances Medication Management With New Release
by Zacks Equity Research
Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.
Abbott's (ABT) Base Volume Rebounds, Lowered View Concerns
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets
by Zacks Equity Research
Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.